Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CURX | 8-K | neutral | 4/10 | Curanex Pharmaceuticals disclosed two newly filed securities class actions related to its August 2025 IPO. Both lawsuits | Oct 19, 2026 |
| SUPN | 8-K | neutral | 2/10 | Supernus Pharmaceuticals filed an 8-K on October 19, 2026, solely to announce the date of its Q3 2026 earnings release a | Oct 19, 2026 |
| CYDY | 8-K | neutral | 5/10 | CytoDyn appointed CFO Robert E. Hoffman as CEO effective October 20, 2026, replacing Dr. Jacob Lalezari who transitions | Oct 19, 2026 |
| VVOS | 8-K | mixed | 6/10 | Vivos Therapeutics closed the acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership interest in SOD' | Oct 19, 2026 |
| MLYS | 8-K | neutral | 2/10 | Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors, expanding the board from | Oct 19, 2026 |
| CRIS | 8-K | bearish | 6/10 | Curis entered into a securities purchase agreement to sell an aggregate of $8,500,006.80 of shares (or pre-funded warran | Oct 19, 2026 |
| IBIO | 8-K | neutral | 3/10 | iBio, Inc. held its 2026 Annual Meeting on October 14, 2026, where stockholders approved an increase in authorized commo | Oct 19, 2026 |
| CRSP | 8-K | neutral | 3/10 | CRISPR Therapeutics announced the promotion of Andrew J. Silver from SVP, Finance to CFO, effective October 19, 2026, re | Oct 19, 2026 |
| VXRT | 8-K | neutral | 3/10 | Vaxart appointed retired Vice Admiral Raquel C. Bono, M.D., to its Board of Directors effective October 16, 2026, pursua | Oct 19, 2026 |
| SCNX | 8-K | bullish | 6/10 | Scienture Holdings reported preliminary Q3 2026 revenue of ~$1.22M, up 256% sequentially from Q2 2026's ~$344K, driven b | Oct 19, 2026 |
| PMHS | 8-K | neutral | 3/10 | Two directors, Alexandra Peterson and Gabrielle Toledano, resigned from the board of Polomar Health Services, effective | Oct 19, 2026 |
| COLL | 8-K | mixed | 5/10 | Collegium Pharmaceutical settled its patent litigation with Grünenthal by paying $17 million to terminate the Grünenthal | Oct 19, 2026 |
| TPST | 8-K | neutral | 2/10 | Tempest Therapeutics appointed John W. Frederick to its board of directors, effective October 13, 2026. Mr. Frederick is | Oct 19, 2026 |
| ADIA | 8-K | neutral | 3/10 | Adia Med, Inc. entered into a Membership Interest Purchase Agreement to sell seven units (7% membership interest) of its | Oct 19, 2026 |
| NRC | 8-K | neutral | 2/10 | NRC Health disclosed that CEO Trent Green was designated as interim principal financial officer on October 14, 2026, wit | Oct 19, 2026 |
| BCDA | 8-K | bullish | 6/10 | BioCardia announced FDA acceptance of its De Novo pre-submission package for the Helix catheter, a transendocardial deli | Oct 19, 2026 |
| MANE | 8-K | bullish | 7/10 | Veradermics announced positive topline Phase 3 data for VDPHL01, an oral extended-release minoxidil, in male pattern hai | Oct 19, 2026 |
| RARE | 8-K | neutral | 4/10 | Ultragenyx settled patent litigation with Navinta LLC over DOJOLVI (triheptanoin), granting Navinta a royalty-free licen | Oct 19, 2026 |
| IRLA | 8-K | neutral | 4/10 | IRulya Therapeutics filed an 8-K furnishing an October 2026 corporate presentation. The presentation highlights Phase 2a | Oct 19, 2026 |
| OSTX | 8-K | bullish | 6/10 | OS Therapies completed an initial closing of a warrant exercise inducement and exchange offer, receiving approximately $ | Oct 19, 2026 |
| DWTX | 8-K | mixed | 6/10 | Dogwood Therapeutics announced a $5 million private placement with its largest shareholder, Sealbond Limited (a subsidia | Oct 19, 2026 |
| AVBP | 8-K | bullish | 6/10 | ArriVent BioPharma announced the publication of Phase 1b (FURMO-002) results for firmonertinib in EGFR PACC-mutant NSCLC | Oct 19, 2026 |
| SLN | 8-K | bullish | 9/10 | Silence Therapeutics plc has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany in an | Oct 19, 2026 |
| CLNN | 8-K | bullish | 7/10 | Clene Inc. announced it has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval of CNM-Au8 fo | Oct 19, 2026 |
| CRMD | 8-K | bullish | 7/10 | CorMedix announced that the FDA has accepted for filing and granted Priority Review to its supplemental New Drug Applica | Oct 19, 2026 |
| MRKR | 8-K | bullish | 5/10 | Marker Therapeutics announced it was awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials Grants | Oct 19, 2026 |
| IRON | 8-K | bullish | 7/10 | Disc Medicine announced positive topline results from the pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic p | Oct 19, 2026 |
| NRXP | 8-K | neutral | 2/10 | NRx Pharmaceuticals filed an 8-K to announce the 2026 Annual Meeting of Stockholders, scheduled for December 17, 2026, w | Oct 16, 2026 |
| ADIL | 8-K | bearish | 5/10 | Adial Pharmaceuticals further adjourned its 2026 Annual Meeting for the fourth time, from October 15 to October 26, 2026 | Oct 16, 2026 |
| IAM | 8-K | neutral | 2/10 | Iambic Therapeutics filed an 8-K on October 16, 2026, reporting the adoption of amended and restated certificate of inco | Oct 16, 2026 |